Leerink Swann cut shares of American Renal Associates (NYSE:ARA) to a market perform rating in a report released on Monday morning, The Fly reports.

A number of other research analysts also recently issued reports on the stock. Morgan Stanley initiated coverage on shares of American Renal Associates in a research report on Friday, December 14th. They issued an equal weight rating on the stock. ValuEngine downgraded shares of American Renal Associates from a hold rating to a sell rating in a research report on Monday, January 7th. Barclays started coverage on shares of American Renal Associates in a research report on Friday, December 14th. They set an equal weight rating and a $18.00 target price on the stock. SunTrust Banks reissued a buy rating and set a $16.00 target price on shares of American Renal Associates in a research report on Wednesday, January 9th. Finally, Deutsche Bank started coverage on shares of American Renal Associates in a research report on Thursday, January 3rd. They set a hold rating and a $12.00 target price on the stock. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the stock. The company currently has an average rating of Hold and an average price target of $17.21.

Shares of American Renal Associates stock opened at $10.23 on Monday. The company has a current ratio of 1.03, a quick ratio of 1.00 and a debt-to-equity ratio of 5.48. American Renal Associates has a 52-week low of $9.20 and a 52-week high of $23.99. The company has a market capitalization of $314.44 million, a PE ratio of 16.77, a PEG ratio of 5.97 and a beta of 2.13.

Hedge funds and other institutional investors have recently made changes to their positions in the business. MetLife Investment Advisors LLC acquired a new stake in American Renal Associates during the 3rd quarter valued at approximately $230,000. Squarepoint Ops LLC acquired a new position in shares of American Renal Associates in the 4th quarter valued at $125,000. Rhumbline Advisers lifted its stake in shares of American Renal Associates by 47.5% in the 4th quarter. Rhumbline Advisers now owns 17,225 shares of the company’s stock valued at $198,000 after purchasing an additional 5,549 shares during the period. Engineers Gate Manager LP lifted its stake in shares of American Renal Associates by 74.4% in the 3rd quarter. Engineers Gate Manager LP now owns 22,892 shares of the company’s stock valued at $496,000 after purchasing an additional 9,764 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of American Renal Associates in the 3rd quarter valued at $606,000. Institutional investors and hedge funds own 95.34% of the company’s stock.

About American Renal Associates

American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.

Further Reading: How Does the Quiet Period Work?

The Fly

Analyst Recommendations for American Renal Associates (NYSE:ARA)

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.